Lung cancer is a malignant disease that starts in lung tissue and includes two major classes: non-small cell lung cancer and small cell lung cancer. It remains one of the leading causes of cancer morbidity and mortality.
Maharashtra will add immunotherapy and PET scans to its state health scheme and open 27 new cancer centres. Separately, the ICMR has issued national guidelines for lung cancer treatment including immunotherapy protocols, as MPs push for expanded access.
Johnson & Johnson faces new talc verdicts in Minnesota and Pennsylvania totaling over $10 million, with 67,000+ lawsuits pending. Meanwhile, the FDA approved a new monthly dosing for RYBREVANT FASPRO, and the company launched its Shockwave C2 Aero coronary catheter globally.
The FDA fast-tracked an inhalable gene therapy for advanced lung cancer after an early 11-patient trial showed tumour shrinkage in three patients and disease stabilization in five. Larger studies involving about 250 patients are underway.
Sino Biopharmaceutical won Chinese approval for a new indication for benmelstobart as maintenance therapy in unresectable stage III NSCLC after chemoradiotherapy. Phase III R-ALPS data showed significantly prolonged progression-free survival versus placebo and a manageable safety profile.
Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
A seminar will present work on KRAS-driven lung cancer and immunotherapy resistance. The research uses immune-competent mouse models and CRISPR-Cas9 screens to identify targets that sensitise tumour cells to T cell-mediated killing.
Aurobindo Pharma's subsidiaries secured Health Canada approval for bevacizumab biosimilar Bevqolva, an EU distribution deal with STADA for two EMA-approved biosimilars, and US FDA approval for ADQUEY ointment for atopic dermatitis.
ImmunityBio has commercially launched ANKTIVA in Saudi Arabia for approved bladder and metastatic non-small cell lung cancer indications. The launch follows accelerated approval in lung cancer and extends the drug’s commercial rollout in MENA.
mRNA cancer vaccines showed promising pancreatic cancer trial results and boosted tumor-fighting drugs in other research. U.S. officials canceled $500 million in vaccine funding, while the NCI is backing a $200 million cancer vaccine partnership.
UAB researchers are advancing cancer prevention, tumor targeting and precision ablation, while AdvanCell is developing targeted alpha therapy and a prostate cancer drug in Phase 1 trials. Both efforts focus on new treatment approaches and research infrastructure.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599943 |
Population Health Management -Increase Lung Cancer Screening in Community Health Centers (LungSMART) |
NOT_YET_RECRUITING | NA |
| NCT07598279 |
Peripheral Vascular Disease as a Clinical Trigger for Opportunistic Lung Cancer Screening Referral: An Implementation Study |
NOT_YET_RECRUITING | NA |
| NCT07596732 |
Statewide Unified Network for Remote Intervention of Strength and Exercise |
NOT_YET_RECRUITING | NA |
| NCT07594834 |
Clinical Study on the Effects of Pulmonary Vessels on Cryoablation and Preventive Embolization Strategies |
NOT_YET_RECRUITING | NA |
| NCT07593248 |
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China |
NOT_YET_RECRUITING | |
| NCT07591376 |
A Reminder App to Improve Physical Activity During Radiotherapy for Lung Cancer - a Pre-study in Healthy Volunteers |
COMPLETED | NA |
| NCT07590440 |
Indian Lung Screening Trial |
NOT_YET_RECRUITING | NA |
| NCT07589101 |
5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors |
NOT_YET_RECRUITING | NA |
| NCT07586826 |
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors |
RECRUITING | PHASE2 |
| NCT07572773 |
CHAMP Lung Cancer Screening Program |
NOT_YET_RECRUITING | NA |
